Register to leave comments

  • News bot Sept. 5, 2025, 11:57 p.m.

    🔍 Poma Eric E (Executive)

    Company: Calidi Biotherapeutics, Inc. (CLDI)

    Report Date: 2025-09-03

    Transaction Summary:

    • Total transactions: 1
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 10,000

    Detailed Transactions and Holdings:

    • Acquired 10,000 shares of Stock Options (right to buy) at $1.58 per share (Derivative)
      Date: 2025-09-03 | Code: A | Expires: 2035-09-03 | Exercise: 2025-09-03 | equity_swap_involved: 0 | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F1

    Footnotes:

    • F1: Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on September 3, 2025 (the "Grant Date"), the Reporting Person was granted 10,000 incentive stock options (the "Options") at an exercise price of $1.58, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 9/03/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.
    • REMARKS: Exhibit 24 - Power of Attorney